FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer-Reference-Cited by-同舟云学术

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

Published:2023-02-24 Issue:2 Volume:18 Page:269-285
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Caligiuri Maureen,Williams Grace L.,Castro Jennifer,Battalagine Linda,Wilker Erik,Yao Lili,Schiller Shawn,Toms Angela,Li Ping,Pardo Eneida,Graves Bradford,Azofeifa Joey,Chicas Agustin,Herbertz Torsten,Lai Maria,Basken Joel,Wood Kenneth W.,Xu Qunli,Guichard Sylvie M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00949-7.pdf

Reference56 articles.

1. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876–84.

2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

3. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30:3019–27.

4. Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11: e0157368.

5. Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017;10:4675–85.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC;2024-04-27

2. Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy;Trends in Pharmacological Sciences;2024-03

3. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants;Cells;2024-01-04

4. Androgen Receptor–Interacting Proteins in Prostate Cancer Development and Therapy Resistance;The American Journal of Pathology;2023-12

5. Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases;Signal Transduction and Targeted Therapy;2023-11-13